FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our "Question of the Day" right now.
FULL SHOWSMissed an episode of Fast Money? Watch the lastest show here.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
With word today that Roche [RHHBY
Loading...
()
] is going hostile and cutting the price of its bid for shares of Genentech [DNA
Loading...
()
] to $42 billion, what should be the first questions on the minds of investors? On CNBC’s Closing Bell, Karen Finerman gives Dylan Ratigan her take on moves in the Pharma market.
Finerman points out that the situation between Roche and Genentech is an interesting deal, as had started in the “old world” and is now continuing in the “new world” of today’s market. She says it is interesting that Roche has gone hostile at this point, as she notes the two companies have been talking for the last six months, unable to come to a deal.
For many reasons, she encourages you to stay close to the story. In two weeks, when Roche has said they will start their tender offer, the company will have to disclose details on the negotiations that had taken place with Genentech.
Finerman believes that after this we could see an offer side from Genentech that could be higher than what we are seeing now. Based on this logic, Finerman says her firm has bought calls, building on an already established position, seeing an upside to the stock down the road, which may ultimately end in a deal between the two companies.
There is also speculation that Roche may have gone hostile in an effort to preempt results coming in April that may boost Genentech’s stock price. Finerman agrees that shortcutting positive future results could be the reason why Roche made the decision to go hostile at this exact moment, and said these concerns would be the first question she would ask of the Roche CEO.
As far as trading individual drug companies, Finerman tends to shy away from the risk inherent in making trades based on individual drug trials, encouraging investing with more diversity.
Instead, Finerman suggests looking into ETFs like XBI [XBI
Loading...
()
] or the IBB [IBB
Loading...
()
] when investing in Pharmaceuticals. She sees big moves in the future of the Pharma market, the “beginning of a wave of consolidation,” and you’re better off playing these ETFs.
Away from Biotech, Procter & and Gamble [PG
Loading...
()
] has been a great defensive place to hide, but Finerman feels that the valuations have become too high for most investors. She suggests staying away from P&G for now, until the valuations come back down. She suggests that Wal-Mart [WMT
Loading...
()
] may have also gotten a little expensive, although it is still a good company based on strong fundamentals. On this name too, the valuations have simply become slightly higher than she’d like to see.
- Your First Move For Tuesday November 17th
- Web Extra: Let's Make A Deal
- Pops & Drops: Dell, FedEx...
- Chartology: Rally Losing Steam?
- Trading The Globe: China
- Wall Street Whale Watching: Noteworthy Moves
- Paulson Betting Unemployment Not Getting Much Worse?
- Stocks Surge To New '09 Highs
- Halftime Report: Will Bernanke's Dollar Talk Sideline Rally?
- Your First Move For Monday November 16th
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to .
CNBC.com with wires
Data is a real-time snapshot *Data is delayed at least 15 minutes